Prognosis of Patients With Infective Endocarditis and Risk Stratification Value of Biomarkers (ENDEAVOR）

Last updated: July 10, 2024
Sponsor: First Affiliated Hospital Xi'an Jiaotong University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cardiovascular Disease

Heart Disease

Cardiac Disease

Treatment

Observational; No Interventions were given.

Clinical Study ID

NCT05965362
XJTU1AF2023LSK-151
  • Ages > 18
  • All Genders

Study Summary

In this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with clinically confirmed infective endocarditis

Exclusion

Exclusion Criteria:

  • Patients refuse to sign informed consent form

  • Patients who combined with serious systemic diseases, cannot tolerate theacquisition of biological samples

Study Design

Total Participants: 2000
Treatment Group(s): 1
Primary Treatment: Observational; No Interventions were given.
Phase:
Study Start date:
May 09, 2024
Estimated Completion Date:
December 31, 2028

Study Description

Infective endocarditis is an inflammation of the inner lining of the heart valves or ventricular walls caused by direct infection of the heart by bacteria, fungi and other microorganisms via the bloodstream route. At present, the clinical diagnosis of IE is mainly based on a combination of typical symptoms, imaging and blood culture, etc. Finding more sensitive means and more accurate indicators for early detection of IE flora distribution characteristics is of great significance for the prevention and targeted treatment of IE. Therefore, in this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.

Connect with a study center

  • First Affiliated Hospital of Xian Jiantong University

    Xi'an, Shaanxi 710061
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.